Though BACE1 and γ-secretase appear to orchestrate axonal pathfinding, researchers doubt inhibitors or modulators of these proteases would cause side effects in people treated for AD.
Prevention trials are testing new protocols for telling potential participants about their heightened risk for dementia, and exploring the psychological effect of such disclosures.
The largest trial yet of ApoE4 carriers is pioneering new protocols with increasing use of technology to reach thousands of potential participants and disclose risk information.
Postmortem pathology confirms that some people who were diagnosed with AD during life had no appreciable amyloid in the brain, leaving researchers to puzzle over what caused their cognitive decline.
The latest optical-clearing technique exposes three-dimensional interactions between plaques, microglia, and blood vessels. It even zooms in on synapses.